Downsizing a thrombus of advanced renal cell carcinoma in a presurgical setting with sorafenib

Urologia Internationalis

Volumn 88, Issue 2, 2012, Pages 235-237

  Takeda, Hirokazu ^a   Nakano, Yojiro ^a   Kashiwagi, Yuhta ^a   Yoshino, Yasushi ^b   Gotoh, Momokazu ^b  

^a TOSEI GENERAL HOSPITAL   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Presurgical setting; Renal cancer; Sorafenib; Tumor thrombus

Indexed keywords

ALPHA INTERFERON; C REACTIVE PROTEIN; SORAFENIB;

ADULT; ADVANCED CANCER; ARTICLE; CASE REPORT; HAND FOOT SYNDROME; HUMAN; KIDNEY CARCINOMA; MALE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; SURGICAL APPROACH; SURGICAL RISK; SURGICAL TECHNIQUE; THROMBECTOMY; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR THROMBUS;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; CHEMOTHERAPY, ADJUVANT; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEPHRECTOMY; PROTEIN KINASE INHIBITORS; PYRIDINES; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; VENA CAVA, INFERIOR; VENOUS THROMBOSIS;

EID: 84859422618     PISSN: 00421138     EISSN: 14230399     Source Type: Journal    
DOI: 10.1159/000334484     Document Type: Article

References (10)

1. Leibovich BC, Blute ML: Surgical management of renal cell carcinoma. Semin Oncol 2006; 33: 552-562. (Pubitemid 44511977)
2. Wood CG: The role of cytoreductive nephrectomy in the management of metastatic renal cell carcinoma. Urol Clin North Am 2003; 30: 581-588. (Pubitemid 37059563)
3. Cowey CL, Amin C, Pruthi RS, et al: Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma. J Clin Oncol 2010; 28: 1502-1507.
4. Shuch B, Riggs SB, LaRochelle JC, et al: Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm. BJU Int 2008; 102: 692-696.
5. Harshman LC, Srinivas S, Kamaya A, Chung BI: Laparoscopic radical nephrectomy after shrinkage of a caval tumor thrombus with sunitinib. Nat Rev Urol 2009; 6: 338-343.
6. Bex A, van der Veldt AA, Blank C, et al: Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery. World J Urol 2009; 27: 533-539.
7. Thomas AA, Rini BI, Lane BR, et al: Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. J Urol 2009; 181: 518-523.
8. Escudier B, Szczylik C, Hutson TE, Demkow T, Staehler M, Rolland F, Negrier S, Laferriere N, Scheuring UJ, Cella D, Shah S, Bukowski RM. Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa- 2a in patients with metastatic renal cell carcinoma. J Clin Oncol 2009 27 1280-1289.
9. Sobin LH: TNM Classification of Malignant Tumors. Oxford, Wiley-Blackwell, 2009.
10. Bex A, Horenblas S, de Gast GC: The timing of immunotherapy and nephrectomy in multimodality treatment of metastatic renal cell carcinoma. Technol Cancer Res Treat 2003; 2: 205-210. (Pubitemid 37121884)